Medical Affairs

---

Clinical Trials

Please click on the identifier number below to view a summary of current and past studies as posted on ClinicalTrials.gov.

XEN1101

ClinicalTrials.gov Identifier NCT03796962: Phase 2b Study to Evaluate XEN1101 as Adjunctive Therapy in Focal Epilepsy

ClinicalTrials.gov Identifier NCT04827901: Investigator-Led Study to Evaluate XEN1101 for Major Depressive Disorder (Icahn School of Medicine at Mount Sinai)

Previous Studies:

ClinicalTrials.gov Identifier NCT03468725: Phase 1b Safety, Tolerability, Pharmacokinetics and Effects on Transcranial Magnetic Stimulation of Oral Doses of XEN1101

ClinicalTrials.gov Identifier NCT03340220: Phase 1a Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of XEN1101

 

XEN496

ClinicalTrials.gov Identifier NCT04639310: XEN496 (Ezogabine) in Children With KCNQ2 Developmental and Epileptic Encephalopathy (EPIK)

 

NBI-921352: Partnered Program with Neurocrine Biosciences (previously XEN901) 

ClinicalTrials.gov Identifier NCT03467100: Phase 1 Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of XEN901

 

Genetic Studies

Xenon is not currently recruiting patients for genetic or epidemiology studies. For more information, please email: research@xenon-pharma.com